2024-03-29, Fri.

Top Stories       Business       Culture & Life       Science & Technology       World

Lecture

Notification

 

NEWS > Science & Technology


Kapruvia approved by European Commission for the treatment of moderate-to-severe pruritus in hemodialysis patients

First approved therapy in Europe for the treatment of chronic kidney disease (CKD)-associated pruritus in hemodialysis patients
Date: 2022-04-28

ST. GALLEN, SWITZERLAND & STAMFORD, CONN.-- April 28, 2022 -- Regulatory News:

Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that the European Commission has granted marketing authorization to Kapruvia® (difelikefalin) for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adult hemodialysis patients. The marketing authorization, which approves Kapruvia® for use in all member states of the European Union plus Iceland, Liechtenstein and Norway, follows the U.S. Food and Drug Administration (FDA) approval of KORSUVA™ (difelikefalin) injection in August 2021 for the same indication. Kapruvia® will be the first therapy available in Europe for the treatment of CKD-associated pruritus in hemodialysis patients.

“We are very excited about the European Commission’s approval of Kapruvia®, marking an important milestone on our journey to advance and fundamentally change the treatment paradigm for people living with the severe burden of pruritus associated with chronic kidney disease,” said Dr. Klaus Henning Jensen, Chief Medical Officer of Vifor Pharma. “We look forward to bringing this first-in-class therapy to patients in Europe, with launch in first markets expected in the second half of 2022.”

“The European Commission’s approval of Kapruvia® provides a much-needed therapy to hemodialysis patients in Europe who suffer from pruritus,” said Dr. Joana Goncalves, Chief Medical Officer of Cara Therapeutics. “We are excited to bring an innovative drug to physicians to help change the way pruritus is managed. We continue to work with our commercial partner VFMCRP, to fill a significant unmet medical need among CKD patients with pruritus in both the U.S. and Europe.”

The approval in Europe is based on pivotal clinical data from two phase-III trials, KALM-1 and KALM-2, as well as supportive data from an additional 32 clinical studies. These studies showed that treatment with Kapruvia® resulted in clinically meaningful improvements in pruritus severity and in pruritus-related quality of life components and was found to be generally well tolerated in patients with moderate-to-severe CKD-associated pruritus.



 to the Top List of News

Notice of Commencement of Operation of Dexerials Photonics Solutions Corporation as Integrated Company Leading Growth in the Photonics Domain
Alphawave Semi and InnoLight Collaborate to Demonstrate Low Latency Linear Pluggable Optics with PCIe 6.0 Subsystem Solution for High-Performance AI
Medisca Opens MAZ Lab in Arizona: An Innovation and Customer Resource Center
Quectel and The Things Industries Announce Partnership to Boost Module Service Management Through LoRaWAN Integration
Efinix Rolls Out Line of FPGAs to Accelerate and Adapt Automotive Designs and Applications
StarFive¡¯s RISC-V Based JH-7110 Intelligent Vision Processing Platform Adopted VeriSilicon¡¯s Display Processor IP
Uniphore Unveils Enhanced Interaction Analytics Solution Powered by Generative AI

 

Laserfiche Announces 2024 Run Smarter Award Winners
LambdaTest and Inflectra Partner to Offer Enhanced Application Lifecyc...
The LYCRA Company joins Performance Days seminar on textile recycling
New Oracle Database Survey Shows Customers Satisfied with Current Rele...
Toshiba Adds New Position Estimation Control Technology to Its Motor C...
Cielo Debuts First Generative AI for Talent Acquisition: CLO.ai
Ventiva Announces Partnership with Clarion for Mass Production of ICE ...
FPT Software Expands Presence in South Korea With Daegu Office Launch
Quectel IoT Modules Significantly More Secure Than Industry Average Ac...
Kymeta Begins Fulfilling Customer Orders of its First Multi-Orbit, On-...

 

 

60, Gamasanro 27gil, Guro-gu, Seoul, Korea, e-mail: news@newsji.com

Copyright, NEWSJI NETWORK.